Moa Life Plus Co., Ltd. (142760)

Overview

Bioleaders Corporation stands at the forefront of the biotechnology industry in South Korea, primarily engaging in the development and commercialization of innovative medical therapies and consumer health products. Founded in 1999, the company has carved a niche in the competitive market through its focus on research and development, particularly in the field of oncology. Bioleaders Corporation's commitment to providing advanced therapeutic solutions is reflected in its diverse product pipeline, which includes cutting-edge drugs and health functional foods intended to improve the quality of life for patients worldwide. Operating from its headquarters in Yongin-Si, South Korea, the company continues to make significant strides in both the medicinal and consumer health sectors, leveraging its scientific expertise to meet the evolving needs of its global customer base.

Products and Services

• P53 Anti-cancer Drug

  A proprietary anti-cancer therapy that targets the P53 gene, known for its role in tumor suppression. This innovative drug is designed to combat cancer by restoring the normal function of P53, offering new hope in the fight against this devastating disease.

• BLS-H01 for Cervical Cancer

  Currently in phase 3 clinical trials, BLS-H01 represents a promising treatment for cervical cancer. This pharmaceutical candidate underscores Bioleaders Corporation's dedication to addressing unmet medical needs in oncology through targeted therapy approaches.

• BLC-H03 Vaccine Adjuvant

  In the preclinical stage, BLC-H03 is being developed as a vaccine adjuvant to enhance the body's immune response to vaccines. This adjuvant has the potential to improve vaccine efficacy, contributing to better health outcomes for individuals worldwide.

• BLS-M07 for Cervical Cancer

  Having completed phase 2b clinical trials, BLS-M07 is another key drug in Bioleaders Corporation’s pipeline, targeting the treatment of cervical cancer. This drug's progression through clinical trials showcases the company's commitment to bringing innovative therapies to the market.

• BLS-M22 for Duchenne Muscular Dystrophy

  This therapeutic candidate, which has completed phase 1 clinical trial, targets Duchenne Muscular Dystrophy (DMD), a rare genetic disorder. BLS-M22 is indicative of Bioleaders Corporation's efforts to extend its research and development activities to include rare diseases.

• Health Functional Foods and Cosmetics

  In addition to its pharmaceutical products, Bioleaders Corporation offers a variety of health functional foods and cosmetic products. These include supplements and skincare products developed using the latest biotechnology research, aimed at enhancing overall wellbeing and health maintenance.